RVMD - Revolution Medicines, Inc.
About Revolution Medicines, Inc. (https://www.revmed.com)
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Mark A. Goldsmith | Chief Executive Officer, President & Chairman | 1962 | $1,709,200 USD |
| Stephen Kelsey Path. FRCP | President of Research & Development | 1961 | $1,094,033 USD |
| Margaret A. Horn | Chief Operating Officer | 1963 | $1,016,166 USD |
| Jack Anders | Chief Financial Officer | 1977 | $874,133 USD |
| Jeff Cislini | Senior Vice President, General Counsel & Corporate Secretary | 1975 | $791,750 USD |
| Xiaolin Wang | Executive Vice President of Development | 1970 | $701,200 USD |
| Adrian Gill | Executive VP & Head of Early Discovery | – | – |
| Alan Bart Sandler | Chief Development Officer | 1957 | – |
| Anthony Mancini | Chief Global Commercialization Officer | 1971 | – |
| Carlos Escobar | VP & Head of Information Security | – | – |
| Erin Graves | Senior Director of Corporate Communications & Investor Relations | – | – |
| Gerwin Winter | Senior VP & GM for the European region | – | – |
| Hieu Le | Vice President of Compliance | – | – |
| Jan Smith | Chief Scientific Officer | – | – |
| Kevan Shokat | Academic Co-Founder & Member of Scientific Advisory Board | – | – |
| Martin D. Burke | Co-Founder & Chairman of Scientific Advisory Board | – | – |
| Michael A. Fischbach | Academic Co-Founder & Member of Scientific Advisory Board | 1981 | – |
| Ryan Asay | Senior Vice President of Corporate Affairs | – | – |
| Walter Reiher | Chief Information Officer | – | – |
| Zhengping Wang | Senior VP of Non-Clinical Development & Clinical Pharmacology | – | – |